<p>Great Efficacy of Afatinib in a Patient with Lung Adenocarcinoma Harboring EGFR L833V/H835L Mutations: A Case Report</p>-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Great Efficacy of Afatinib in a Patient with Lung Adenocarcinoma Harboring EGFR L833V/H835L Mutations: A Case Report

Published:2020-10 Issue: Volume:Volume 13 Page:10689-10692
ISSN:1178-6930
Container-title:OncoTargets and Therapy
language:en
Short-container-title:OTT

Author:

Long Xiang,Qin Tian,Lin Junhong

Publisher

Informa UK Limited

Subject

Pharmacology (medical),Oncology

Reference20 articles.

1. Worldwide Frequency of Commonly Detected EGFR Mutations

2. Nonsmall cell lung cancer with rare exon 7 p.A289V mutation in the EGFR gene responds to Icotinib treatment

3. Case Report: Osimertinib achieved remarkable and sustained disease control in an advanced non-small-cell lung cancer harboring EGFR H773L/V774M mutation complex

4.

Great efficacy of afatinib on a patient with lung adenocarcinoma harboring uncommon EGFR delE709_T710insD mutations: a case report

5. First-generation EGFR tyrosine kinase inhibitor therapy in 106 patients with compound EGFR -mutated lung cancer: a single institution's clinical practice experience

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Successful treatment of lung adenocarcinoma complicated with a rare compound EGFR mutation L833V/H835L using aumolertinib: a case report and literature review;Frontiers in Pharmacology;2023-08-29

2. Afatinib for the Treatment of NSCLC with Uncommon EGFR Mutations: A Narrative Review;Current Oncology;2023-05-28

3. EGFR p.V774M/p.L833V compound mutations in lung adenocarcinoma responded well to almonertinib: a case report;Frontiers in Oncology;2023-05-12

4. Complete response to first-line osimertinib monotherapy in a complex epidermal growth factor receptor mutant (L833V/H835L) lung adenocarcinoma patient: a case report;Anti-Cancer Drugs;2023-04-28

5. A case report of a lung cancer patient with two uncommon EGFR mutations and a review of the literature: two sides of the same coin;Anti-Cancer Drugs;2023-03-10

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3